Lymphoepithelioma-like Hepatocellular Carcinoma
Anthony W.H. Chan(Chinese University of Hong Kong), Ka‐Fai To(Chinese University of Hong Kong), Stephen L. Chan(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Grace Lai‐Hung Wong(Chinese University of Hong Kong), Vincent Wai‐Sun Wong(Chinese University of Hong Kong), Yi Pan(Shenzhen University), Joanna H. Tong(Chinese University of Hong Kong)
Cited by 78
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k